CAMP4 Therapeutics Stock
CAMP4 Therapeutics Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Joshua Mandel-Brehm
- Employees
- 48
- Market cap
- $199 M
- IPO
- 11/10/2024
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
CAMP4 Therapeutics stock: price history
1D
-8.1%
1W
-15.9%
1M
-17.9%
6M
-29.4%
YTD
-48.3%
1Y
+1.9%
2Y
-71.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~0% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about CAMP4 Therapeutics
Analyst assessment of CAMP4 Therapeutics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$9.67
MEDIAN
US$8.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
16
BUY
7
HOLD
1
SELL
0
STRONG SELL
24
TOTAL · Buy
As of: 29/09/2026
CAMP4 Therapeutics stock metrics
P/E
-1.42
P/B
-264.99
EV/EBITDA
-1.57
RETURN ON EQUITY
4,838.4%
NET MARGIN
-1,884.8%
DEBT/EQUITY
-3.42
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
69.1%
FLOAT SHARES
43,332,967
AVG. DAILY VOLUME (30D)
270,087
Insider transactions (SEC)
Gold Kelly
Schwab Andrew J.
Schwab Andrew J.
Schwab Andrew J.
Schwab Andrew J.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about CAMP4 Therapeutics stock
What does CAMP4 Therapeutics do?
CAMP4 Therapeutics Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Joshua Mandel-Brehm, the company employs around 48 people.
The IPO was on 11/10/2024; the stock trades on NASDAQ under the ticker CAMP.
What do analysts say about CAMP4 Therapeutics stock?
24 analysts rate the stock, the consensus is Buy (as of 29/09/2026).
The average price target is US$9.67, ranging from US$6.00 to US$15.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does CAMP4 Therapeutics report next?
Around past earnings, price swings were roughly 0% stronger than usual.
Does CAMP4 Therapeutics pay a dividend?
No, CAMP4 Therapeutics currently does not pay a dividend.
Which stocks are comparable to CAMP4 Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get CAMP4 Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess CAMP4 Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.